Дипептиды либо органоспецифичны, либо широко присутствуют в различных тканях. Vesilute — один из последних дипептидов, который обнаруживается по всему организму [1]. Vesilute — один из наименее изученных пептидов Хавинсона, однако он показал некоторое влияние на ткани мочевого пузыря и мочеполовой системы. Отчеты исследований показывают, что Vesilute может улучшить функцию мочевого пузыря, особенно у пожилых людей, помогая при хроническом цистите, доброкачественной гиперплазии предстательной железы (ДГПЖ) и различных проблемах с мочеиспусканием. Пептид также оказывает важное органотрофическое действие на простату, помогая предотвратить пролиферацию клеток и увеличение простаты. Исследования показывают, что этот эффект может быть результатом улучшения микроциркуляции.

Vesilute и другие цитомедины, по-видимому, оказывают благотворное влияние на качество спермы и фертильность. Исследования за пределами России указывают на увеличение выработки спермы, ее здоровья и жизнеспособности при применении цитомединов. Кроме того, наблюдается уменьшение количества аномальных сперматозоидов. Все эти эффекты способствуют повышению рождаемости[2].

Интересно, что пептид Glu-Asp, наряду с двенадцатью другими дипептидами, отвечает за вкус умами в различных условиях[3]. Хотя это не имеет прямого отношения к здоровью и хорошему самочувствию, тот факт, что эти пептиды производят желаемый вкус, предполагает, что их употребление в пищу может стимулироваться с помощью эволюционных механизмов вкуса. Это могло бы, хотя и не было доказано, указывать на то, что эти пептиды играют важную роль в основных биохимических процессах. Было показано, что везилют и другие цитомедины активны при пероральном приеме [2].

Аминокислотная последовательность:Глу-Асп (ЭД)
Молекулярная формула:С₉ЧАС₁₄Н₂О₇Молекулярный вес: 262.20 g/mol
PubChem CID: 99716
CAS Number: 3918-84-1
Synonyms: alpha-glutamylaspartic acid, SCHEMBL1674753, vesilut, ED dipeptide

Source: PubChem

Vesilute is thought to have anti-aggregation effects on the muscles of the bladder wall. In muscle, glycogen serves as an important form of energy storage. This multibranched polysaccharide is a short-term energy storage solution and is found primarily in muscle and liver cells. It makes up approximately 2% of muscle mass where it serves as an immediate source of glucose to maintain contraction.

Glycogen is broken down by an enzyme called glycogen phosphorylase. At rest, glycogen phosphorylase B is in a tense state due to the presence of ATP and certain enzymes. In its tense form, phosphorylation B is unable to bind with glycogen and therefore cannot break it down[4], [5]. Without the ability to breakdown glycogen into glucose, muscle is unable to maintain contraction and is forced to relax.

There are multiple stimuli for aggregation in skeletal muscle including the generation of thermal energy (heat), increases in AMP levels, and increases in calcium ion levels. Vesilute appears to interfere with the process of aggregation at a universal step, thereby preventing glycogen breakdown by any mechanism. This, in turn, induces smooth muscle relaxation. Relaxation of smooth muscle ends the signals calling for more energy and can help to break the cycle that leads to spasm. Because smooth muscle is dependent on calcium signals for maintenance, breaking the spasmodic cycle by reducing calcium levels and dissipating heat can lead to long-term relief from spasm. These effects would be highly prominent in the urinary tract where smooth muscle is abundant.

Vesilute and Blood Vessels

The effects of Vesilute, which is considered to be a cytomedine peptide, would also be prominent in the vasculature where smooth muscle reigns supreme. Cytomedines, according to Vladimir Khavinson, are peptide bioregulators that prevent premature aging[6]. In this case, interruption of aggregation would lead to vessel relaxation. This would lead to lower blood pressure, reduced energy expenditure in the heart, and improved nutrient delivery to organs throughout the body. Thus, Vesilute 20mg likely has beneficial effects on blood pressure, the long-term health of the vascular system, and several end organs like the heart, brain, and kidneys.

It is thought that the benefits of Vesilute on the prostate are due to its microvascular effects. Improved circulation in the prostate helps to reduce inflammation, improve blood flow, and rid the prostate of toxins. The net effect of improved microvascular circulation in the prostate is a decrease in fibrosis and enlargement of the prostate gland. Research shows that prostate massage has a similar effect.

Vesilute and Fertility

Interestingly, decreasing prostatitis by increasing microvascular supply to the gland via cytomedines like Vesilute appears to have an impact on spermatogenesis. Sperm levels following treatment of prostatitis increase as much as 29% and show more than a 14% increase in viability[7]. Research shows that men treated with cytomedines like Vesilute experience an increase in fertility without intolerable side effects.

Vesilute Summary

Vesilute is a Khavinson peptide with research exploring its role in regulating the urinary tract and prostate gland. Research evidence indicates that Vesilute may help to relieve symptoms associated with bladder and urinary tract dysfunction. Vesilute and other cytomedines have been shown to reduce prostate dysfunction and are thought to act by improving microcirculation in the prostate and by reducing cell proliferation. The latter effect may be due to changes in chromosome density and epigenetic factors, a mechanism of cellular regulation that is common among Khavinson peptides.

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of genome peptide regulation” (Karger AG, 2005). Vladimir Khavinson introduced scientific specialty “Gerontology and Geriatrics” in the Russian Federation on the governmental level. Academic Council headed by V. Khavinson has oversighted over 200 Ph.D. and Doctorate theses from many different countries.

Prof. Vladimir Khavinson is being referenced as one of the leading scientists involved in the research and development of Vesilute. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between

1. E. Heidenreich et al., “A Novel UPLC-MS/MS Method Identifies Organ-Specific Dipeptide Profiles,” Int. J. Mol. Sci., vol. 22, no. 18, p. 9979, Sep. 2021, doi: 10.3390/ijms22189979.
2. A. A. Kamalov, E. A. Efremov, S. D. Dorofeev, and S. M. Paniushkin, “[Use of oral vitaprost in the treatment of chronic abacterial prostatitis],” Urol. Mosc. Russ. 1999, no. 5, pp. 45–50, Oct. 2006.
3. Y. Kong et al., “Comparison of non-volatile umami components in chicken soup and chicken enzymatic hydrolysate,” Food Res. Int., vol. 102, pp. 559–566, Dec. 2017, doi: 10.1016/j.foodres.2017.09.038.
4. T. B. Eronina et al., “Effect of GroEL on thermal aggregation of glycogen phosphorylase b from rabbit skeletal muscle,” Macromol. Biosci., vol. 10, no. 7, pp. 768–774, Jul. 2010, doi: 10.1002/mabi.200900396.
5. “Glycogen Phosphorylase B – an overview | ScienceDirect Topics.” https://www.sciencedirect.com/topics/neuroscience/glycogen-phosphorylase-b (accessed Feb. 26, 2022).
6. V. G. Morozov and V. K. Khavinson, “[Prospects of cytomedines application in clinical medicine and gerontology],” Klin. Med. (Mosk.), vol. 78, no. 2, pp. 42–45, 2000.
7. B. A. Neymark, A. I. Neymark, A. V. Davydov, I. I. Klepikova, N. A. Nozdrachev, and M. V. Razdorskaya, “[ROLE OF CYTOMEDINES IN THE TREATMENT OF PATIENTS WITH CHRONIC PROSTATITIS ASSOCIATED WITH IMPAIRED SPERMATOGENESIS],” Urol. Mosc. Russ. 1999, no. 5, pp. 70, 72–73, Oct. 2015

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.